BR112022011584A2 - Métodos para tratamento da doença de parkinson - Google Patents
Métodos para tratamento da doença de parkinsonInfo
- Publication number
- BR112022011584A2 BR112022011584A2 BR112022011584A BR112022011584A BR112022011584A2 BR 112022011584 A2 BR112022011584 A2 BR 112022011584A2 BR 112022011584 A BR112022011584 A BR 112022011584A BR 112022011584 A BR112022011584 A BR 112022011584A BR 112022011584 A2 BR112022011584 A2 BR 112022011584A2
- Authority
- BR
- Brazil
- Prior art keywords
- subject
- parkinson
- disease
- methods
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y401/00—Carbon-carbon lyases (4.1)
- C12Y401/01—Carboxy-lyases (4.1.1)
- C12Y401/01015—Glutamate decarboxylase (4.1.1.15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962947418P | 2019-12-12 | 2019-12-12 | |
| PCT/US2020/064928 WO2021119615A1 (en) | 2019-12-12 | 2020-12-14 | Methods for treating parkinson's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022011584A2 true BR112022011584A2 (pt) | 2022-12-13 |
Family
ID=76330812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022011584A BR112022011584A2 (pt) | 2019-12-12 | 2020-12-14 | Métodos para tratamento da doença de parkinson |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230050187A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4072568A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7758671B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220114028A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020403266A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022011584A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3161322A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL293776B1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022007193A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021119615A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026085129A1 (en) * | 2024-10-15 | 2026-04-23 | MeiraGTx Neuro I, LLC | High-dose gad gene therapy for treating parkinson's disease |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001089583A2 (en) * | 2000-05-23 | 2001-11-29 | Neurologix, Inc. | Glutamic acid decarboxylase (gad)_delivery system for treating neurodegenerative diseases |
| US7695959B2 (en) * | 2000-05-23 | 2010-04-13 | Neurologix, Inc. | Glutamic acid decarboxylase (GAD) based delivery systems |
| US20030087264A1 (en) * | 2001-05-22 | 2003-05-08 | Kaplitt Michael G. | Transcriptional regulation of target genes |
| EP1893754A4 (en) * | 2005-05-31 | 2009-01-21 | Neurologix Inc | NEW GLUTAMIC ACID DECARBOXYLASE (GAD) CHIMESES AND USE PROCESSES |
| JOP20190269A1 (ar) * | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
-
2020
- 2020-12-14 CA CA3161322A patent/CA3161322A1/en active Pending
- 2020-12-14 MX MX2022007193A patent/MX2022007193A/es unknown
- 2020-12-14 EP EP20898391.6A patent/EP4072568A4/en active Pending
- 2020-12-14 BR BR112022011584A patent/BR112022011584A2/pt unknown
- 2020-12-14 JP JP2022535694A patent/JP7758671B2/ja active Active
- 2020-12-14 IL IL293776A patent/IL293776B1/en unknown
- 2020-12-14 AU AU2020403266A patent/AU2020403266A1/en active Pending
- 2020-12-14 KR KR1020227023752A patent/KR20220114028A/ko active Pending
- 2020-12-14 US US17/784,510 patent/US20230050187A1/en active Pending
- 2020-12-14 WO PCT/US2020/064928 patent/WO2021119615A1/en not_active Ceased
-
2025
- 2025-10-09 JP JP2025171111A patent/JP2025188191A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220114028A (ko) | 2022-08-17 |
| US20230050187A1 (en) | 2023-02-16 |
| EP4072568A1 (en) | 2022-10-19 |
| EP4072568A4 (en) | 2024-02-07 |
| JP7758671B2 (ja) | 2025-10-22 |
| MX2022007193A (es) | 2022-09-19 |
| JP2023506007A (ja) | 2023-02-14 |
| IL293776B1 (en) | 2026-07-01 |
| WO2021119615A1 (en) | 2021-06-17 |
| AU2020403266A1 (en) | 2022-08-04 |
| CA3161322A1 (en) | 2021-06-17 |
| JP2025188191A (ja) | 2025-12-25 |
| IL293776A (en) | 2022-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Marino et al. | Parkinson’s disease: a review from pathophysiology to treatment | |
| Park et al. | Human adipose tissue‐derived mesenchymal stem cells improve cognitive function and physical activity in ageing mice | |
| Fitzgerald et al. | An open label trial of clustered maintenance rTMS for patients with refractory depression | |
| Thompson et al. | Spatiotemporal patterns of gene expression around implanted silicon electrode arrays | |
| Tan et al. | Angelman syndrome: current and emerging therapies in 2016 | |
| Knott et al. | Cyclic AMP signaling: a molecular determinant of peripheral nerve regeneration | |
| Crombie et al. | Aerobic exercise and consolidation of fear extinction learning among women with posttraumatic stress disorder | |
| RU2693462C2 (ru) | Лечение заболеваний, связанных с сиртуином (sirt), путем ингибирования природного антисмыслового транскрипта к сиртуину (sirt) | |
| BR112021017720A2 (pt) | Sistemas e métodos para tratamento de distúrbios respiratórios do sono | |
| BR112018076124A2 (pt) | tratamento de amd utilizando a variante de aav2 com aflibercept | |
| BR112021021921A2 (pt) | Agente, uso de um agente e método de tratamento ou prevenção de uma doença metabólica | |
| BR112015017775A2 (pt) | enzima cistationina beta-sintase para o tratamento de homocistinúria | |
| BR112012008038A2 (pt) | sistema para estimulação do nervo trigêmeo para tratamento de um distúrbio neuropsiquiátrico, unidade de eletrodo subcutâneo, método para tratar um distúrbio neuropsiquiátrico, e, kit para estimulação do nervo trigêmeo para tratamento de um distúrbio neuropsiquiátrico | |
| ATE280590T1 (de) | Glutaminsäure decarboxylase (gad) abgabesystem zur behandlung neurodegeneraliver erkrankungen | |
| WO2005004794A3 (en) | Method of treating neurodegenerative disease | |
| CY1125450T1 (el) | Ευγευστες συνθεσεις οι οποιες περιλαμβανουν φαινυλοβουτυρικο νατριο και χρησεις αυτων | |
| MX2010003548A (es) | Metodos para el tratamiento de padecimientos neurologicos autoinmunes con ciclofosfamida. | |
| MX2021011269A (es) | Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina. | |
| EP4591708A3 (en) | Gene therapy for stxbp1 encephalopathy | |
| BR112018008344A2 (pt) | molécula de ácido nucleico, composição farmacêutica, vetor ou célula, método para prevenir, tratar ou melhorar uma doença, e, uso de uma composição | |
| MX2024000237A (es) | Arnip que inhibe la expresión del gen angptl3 y uso del mismo. | |
| JP2020533281A (ja) | デキストラン硫酸の新規使用 | |
| WO2005037211A3 (en) | Methods and compositions for the treatment of neurological disease | |
| PH12020551191A1 (en) | Oligodendrocyte-specific promoter, mirna specific to plp1 gene, vector including said promoter and/or mirna, and pharmaceutical composition including said vector | |
| WO2019118951A3 (en) | Compositions and methods of enhancing the homing and/or engraftment of hematopoietic cells in the central nervous system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: MEIRAGTX NEURO I, LLC (US) |